BIOCRYST PHARMACEUTICALS INC (BCRX)
US09058V1035 - Common Stock
We assign a fundamental rating of 2 out of 10 to BCRX. BCRX was compared to 577 industry peers in the Biotechnology industry. BCRX may be in some trouble as it scores bad on both profitability and health. BCRX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BCRX has reported negative net income.
In the past year BCRX has reported a negative cash flow from operations.
In the past 5 years BCRX always reported negative net income.
BCRX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
BCRX has a Return On Assets (-44.58%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.58% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-40.02%
ROA(5y)-47.36%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of BCRX (98.56%) is better than 98.26% of its industry peers.
In the last couple of years the Gross Margin of BCRX has remained more or less at the same level.
BCRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.92%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
BCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BCRX has been increased compared to 1 year ago.
The number of shares outstanding for BCRX has been increased compared to 5 years ago.
BCRX has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -3.18, we must say that BCRX is in the distress zone and has some risk of bankruptcy.
BCRX's Altman-Z score of -3.18 is in line compared to the rest of the industry. BCRX outperforms 42.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.18 |
ROIC/WACCN/A
WACC9.57%
2.3 Liquidity
BCRX has a Current Ratio of 3.73. This indicates that BCRX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.73, BCRX perfoms like the industry average, outperforming 40.24% of the companies in the same industry.
A Quick Ratio of 3.48 indicates that BCRX has no problem at all paying its short term obligations.
BCRX's Quick ratio of 3.48 is on the low side compared to the rest of the industry. BCRX is outperformed by 61.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.73 | ||
| Quick Ratio | 3.48 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 27.27% over the past year.
The Revenue has grown by 22.68% in the past year. This is a very strong growth!
The Revenue has been growing by 74.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.29%
Revenue 1Y (TTM)22.68%
Revenue growth 3Y165.04%
Revenue growth 5Y74.13%
Sales Q2Q%34.87%
3.2 Future
The Earnings Per Share is expected to grow by 24.29% on average over the next years. This is a very strong growth
Based on estimates for the next years, BCRX will show a quite strong growth in Revenue. The Revenue will grow by 18.51% on average per year.
EPS Next Y38.2%
EPS Next 2Y28.94%
EPS Next 3Y27.56%
EPS Next 5Y24.29%
Revenue Next Year22.81%
Revenue Next 2Y20.4%
Revenue Next 3Y19.5%
Revenue Next 5Y18.51%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
BCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BCRX's earnings are expected to grow with 27.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.94%
EPS Next 3Y27.56%
5. Dividend
5.1 Amount
No dividends for BCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOCRYST PHARMACEUTICALS INC
NASDAQ:BCRX (7/25/2024, 7:00:02 PM)
Premarket: 7.61 +0.06 (+0.79%)7.55
+0.15 (+2.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.56B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.58% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.56% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.73 | ||
| Quick Ratio | 3.48 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y38.2%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)22.68%
Revenue growth 3Y165.04%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y